Membrane and envelope virus proteins co-expressed as lysosome associated membrane protein (LAMP) fused antigens: a potential tool to develop DNA vaccines against flaviviruses.
Vaccination is the most practical and cost-effective strategy to prevent the majority of the flavivirus infection to which there is an available vaccine. However, vaccines based on attenuated virus can potentially promote collateral side effects and even rare fatal reactions. Given this scenario, the development of alternative vaccination strategies such as DNA-based vaccines encoding specific flavivirus sequences are being considered. Endogenous cytoplasmic antigens, characteristically plasmid DNA-vaccine encoded, are mainly presented to the immune system through Major Histocompatibility Complex class I - MHC I molecules. The MHC I presentation via is mostly associated with a cellular cytotoxic response and often do not elicit a satisfactory humoral response. One of the main strategies to target DNA-encoded antigens to the MHC II compartment is expressing the antigen within the Lysosome-Associated Membrane Protein (LAMP). The flavivirus envelope protein is recognized as the major virus surface protein and the main target for neutralizing antibodies. Different groups have demonstrated that co-expression of flavivirus membrane and envelope proteins in mammalian cells, fused with the carboxyl-terminal of LAMP, is able to induce satisfactory levels of neutralizing antibodies. Here we reviewed the use of the envelope flavivirus protein co-expression strategy as LAMP chimeras with the aim of developing DNA vaccines for dengue, West Nile and yellow fever viruses.
Dhalia
Rafael
R
Fundação Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhães, Departamento de Virologia, Laboratório de Virologia e Terapia Experimental, Recife, PE, Brasil. rdhalia@cpqam.fiocruz.br
Maciel
Milton
M
Cruz
Fábia S P
FS
Viana
Isabelle F T
IF
Palma
Mariana L
ML
August
Thomas
T
Marques
Ernesto T A
ET
D003715:Dengue / Q000276:immunology / Q000517:prevention & control; D005416:Flavivirus / Q000737:chemistry / Q000276:immunology*; D018177:Flavivirus Infections / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D051907:Lysosomal Membrane Proteins / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*; D014901:West Nile Fever / Q000276:immunology / Q000517:prevention & control; D015004:Yellow Fever / Q000276:immunology / Q000517:prevention & control
D051907:Lysosomal Membrane Proteins; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines